RxDoctor Payments Data

William Fenton, MD

Family Medicine · Hamilton, OHNPI 1497819304

Payments from drug & device makers

$6,468in general payments, 2019–2025

Across 472 payments — averaging $13.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$938
  • AstraZeneca$616
  • Astellas Pharma US Inc$538
  • GSK$323
  • Johnson & Johnson$301
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$6,468100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,468 in reported general payments places this provider in the 90th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$81,224
Medicare patients
255
Services billed
1,162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$105,688
EliquisApixaban50$69,575
MounjaroTirzepatide50$68,443
JardianceEmpagliflozin46$49,289
JanuviaSitagliptin Phosphate30$38,800
MyrbetriqMirabegron59$38,540
TrulicityDulaglutide11$22,449
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog21$22,061
XareltoRivaroxaban15$18,636
LinzessLinaclotide20$11,275
Lantus SolostarInsulin Glargine,hum.Rec.Anlog61$10,871
Bydureon BciseExenatide Microspheres13$10,580
MovantikNaloxegol Oxalate13$9,758
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$6,598
Levemir FlexpenInsulin Detemir24$6,341

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$938$105,68880 claims
Lilly USA, LLCMounjaro, Trulicity$273$90,89261 claims
PfizerEliquis$228$69,57550 claims
Boehringer IngelheimJardiance, Stiolto Respimat$165$55,88760 claims
MerckJanuvia$247$38,80030 claims
Astellas Pharma US IncMyrbetriq$538$38,54059 claims
Johnson & JohnsonXarelto$301$18,63615 claims
AbbVieLinzess, Synthroid$1,516$12,97743 claims
AstraZenecaSymbicort$616$5,07220 claims
GSKArnuity Ellipta$323$2,08911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Hamilton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →